HOME
SEARCH
RSS FEED
SUBSCRIBE
Treatment of Acute Myeloid Leukemia (AML) with the Multi-kinase FLT3-IRAK1/4 Inhibitor, NCGC1481, to Avoid Adaptive Resistance
Case ID:
TAB-3588
Web Published:
12/6/2022
Description:
This technology includes the identification and use of a novel small molecule, NCGC1481, to inhibit both the FLT3 and IRAK1/4 kinase pathways for treating acute myeloid leukemia (AML). An activating mutation of the FMS-like receptor kinase 3 (FMT3) occurs in approximately 25% of AML cases. Consequently, FLT3 inhibitors (FLT3i) have a good initial clinical response, however patients relapse with FLT3i-resistance. This adaptive resistance following FLT3i treatment is partially conferred by activation of the IRAK1/4 kinase complex. Given the challenges of achieving multi-drug combination regimens, a high-throughput screen was performed to identify compounds that could inhibit both FLT3i and IRAK1/4 kinases simultaneously. The multi-kinase FLT3-IRAK1/4 inhibitor NCGC1481eliminated adaptive resistant FLT3-ITD AML cells in vitro and in vivo, and displayed superior efficacy as compared to current targeted FLT3 therapies.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech?title=Treatment_of_Acute_Myeloid_Leu kemia_(AML)_with_the_Multi-kinase_FLT3-IRAK1%2f4_Inhibitor%2c_NCGC1481%2c_to _Avoid_Adaptive_Resistance
Category(s):
Therapeutics
Oncology
Research Materials
Bookmark this page
Download as PDF
For Information, Contact:
Ami Gadhia
Technolgy and Patent Specialist
NIH Technology Transfer
301-827-7159
ami.gadhia@nih.gov
Inventors:
Jian-kang Jiang
Craig Thomas
Keywords:
FTL3/IRAK
Inhibitors
MOLECULE
Small
VCXXXX
WIXXXX
WKXXXX
XEXXXX
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum